Delivery Order SPE2DR25D2013-SPE2DR26F5QMC
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of RINVOQ ER 15 mg tablets in quantities of 30 units. This competitively awarded, non-set-aside contract carries a ceiling value of $6,223.32 and is structured as a firm fixed price delivery order with an ultimate completion date of August 14, 2025. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 29, 2025, for the supply of RINVOQ ER 45 mg tablets (28-count units) under a firm fixed-price contract valued at $15,357.41. This non-set-aside delivery order, with an ultimate completion date of September 30, 2025, represents a procurement of pharmaceutical products to support federal medical supply requirements. The order will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 27, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units) under a firm fixed-price contract with a ceiling value of $8,045.70. This is a non-set-aside, competitively awarded delivery order with an ultimate completion date of May 28, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for supply of RINVOQ ER 15 mg tablets in quantities of 30, with a ceiling value of $17,975.65. This is a firm fixed-price delivery order with no set-aside designation, awarded on a competitive basis. The contract is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 24, 2025. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units) valued at $12,222.99. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 8, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award does not utilize a set-aside designation, indicating the contract was competed openly among...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on October 20, 2025, for the supply of RINVOQ ER 15 mg tablets in quantities of 30 units. This competitively awarded, non-set-aside contract has a ceiling value of $34,587.54 and is structured as a firm fixed price delivery order with an ultimate completion date of October 21, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of RINVOQ ER 15 mg tablets in quantities of 30 units. This competitively awarded, non-set-aside contract is valued at $12,114.96 and utilizes firm fixed price terms, with an ultimate completion date of September 4, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 27, 2025, for the supply of RINVOQ ER 30 mg tablets in quantities of 30 units. This competitive award, valued at $12,446.64, represents a firm fixed-price delivery order with an ultimate completion date of September 29, 2025. The contract was placed with no set-aside designation, indicating full and open competition. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units) under a firm fixed-price contract with a ceiling value of $6,223.30. This non-competitive delivery order is scheduled for ultimate completion by August 12, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of RINVOQ ER 15 mg tablets in quantities of 30 units. This competitively awarded, non-set-aside contract carries a ceiling value of $27,956.70 and utilizes firm fixed-price pricing, with an ultimate completion date of September 22, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- SPE2DR25D2013Indefinite Delivery Contract
- SPE2DR25D2013-SPE2DR26F5QMCDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 7, 2025, for the supply of RINVOQ ER 15 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with a ceiling value of $30,179.16 and an ultimate completion date of November 10, 2025. The contract carries no set-aside designation, indicating it was competitively awarded. Performance will be executed at the company's Corporate Office facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and extending through December 2026. This comprehensive pharmaceutical support vehicle enables AmerisourceBergen to supply a broad range of medications and medical supplies to support military healthcare programs globally. The company, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement and has demonstrated consistent capability to meet competitive federal procurement requirements across numerous therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $30.2k | 11/7/25 |